2022
DOI: 10.1111/ejh.13807
|View full text |Cite
|
Sign up to set email alerts
|

Venous thromboembolism prophylaxis in hospitalized sickle cell disease and sickle cell trait patients

Abstract: Introduction Sickle trait (Hb SA) or sickle disease (Hb SS) carries increased risk of venous thromboembolism (VTE). Hb SS patients are young and lack common comorbid conditions that qualify them for VTE prophylaxis (VTEP). Methods Retrospective, multicenter analysis of Hb SS/Hb SA adult patients between January 2013 and December 2018. Results There were 803 Hb SA (525 patients) and 1020 Hb SS admissions (262 patients). VTEP use was similar between Hb SA and controls (42% vs. 46%; p‐value = .06) and Hb SS and c… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
6
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(6 citation statements)
references
References 19 publications
0
6
0
Order By: Relevance
“…In our investigation, a notable 73.4% of participants were beneficiaries of some anticoagulation regimen, a proportion that markedly surpasses literature benchmarks, potentially elucidating the attenuated VTE event rates in our cohort [35,38]. The rationale for anticoagulation spans from prior VTE episodes and in-hospital thromboprophylaxis to management strategies for vaso-occlusive crises.…”
Section: Discussionmentioning
confidence: 76%
See 1 more Smart Citation
“…In our investigation, a notable 73.4% of participants were beneficiaries of some anticoagulation regimen, a proportion that markedly surpasses literature benchmarks, potentially elucidating the attenuated VTE event rates in our cohort [35,38]. The rationale for anticoagulation spans from prior VTE episodes and in-hospital thromboprophylaxis to management strategies for vaso-occlusive crises.…”
Section: Discussionmentioning
confidence: 76%
“…The pronounced incidence of VTE events in hospitalized and ambulatory SCD patients underscores the imperative need for a comprehensive evaluation of thromboprophylaxis practices tailored to this demographic. Alarmingly, there appears to be a suboptimal utilization of thromboprophylaxis, with reported usage rates oscillating between 14.4% in adolescents to 45% in adult SCD patients [34,35]. These figures are disconcertingly low, especially when juxtaposed against the inherent VTE risk in this population.…”
Section: Discussionmentioning
confidence: 96%
“…Similarly, in a retrospective multi-centre study of hospitalized adults with HbSS the odds of TP use during admission varied by treatment site. 94 The fact that certain treatment sites tend to offer TP more frequently than others suggests the possibility of a group of physicians who either underestimate the thrombosis risk associated with SCD or, conversely, recognize the elevated thrombosis risk but have concerns about an increased risk of bleeding. This observation is significant and emphasizes the need for evidence to inform practice.…”
Section: R E Se a Rch Ga Ps I N This A R E Amentioning
confidence: 99%
“…Interestingly, this study highlighted the variability of TP between the 48 paediatric hospitals studied, where the percentage of adolescents who received TP ranged from 0% to as high as 62%. Similarly, in a retrospective multi‐centre study of hospitalized adults with HbSS the odds of TP use during admission varied by treatment site 94 . The fact that certain treatment sites tend to offer TP more frequently than others suggests the possibility of a group of physicians who either underestimate the thrombosis risk associated with SCD or, conversely, recognize the elevated thrombosis risk but have concerns about an increased risk of bleeding.…”
Section: Research Gaps In This Areamentioning
confidence: 99%
“…Ongoing investigations have also begun to evaluate the utility of additional antithrombotic and anticoagulative agents in SCD VTE treatment and prophylaxis, but further investigation is needed to characterize the thrombotic pathways active in SCD, so agents that best target them can be identified. [ 39 ▪ , 40 ▪ ].…”
Section: Von Willebrand Factor and Its Role In Sickle Cell Disease Pa...mentioning
confidence: 99%